HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.
about
Pros and Cons of Antigen-Presenting Cell Targeted Tumor VaccinesTargeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.A novel synthetic bipartite carrier protein for developing glycotope-based vaccines.DNA vaccination against oncoantigens: A promise.The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2(+) mammary cancer.
P2860
HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.
@ast
HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.
@en
type
label
HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.
@ast
HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.
@en
prefLabel
HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.
@ast
HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.
@en
P2093
P2860
P50
P1476
HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy
@en
P2093
Aurelia Rughetti
Federica Riccardo
Federica Taurino
Filippo Veglia
Francesca Belleudi
Hassan Rahimi
Ilaria Grazia Zizzari
Luigi Frati
Maria Rosaria Torrisi
Marianna Nuti
P2860
P2888
P304
P356
10.1007/S00109-011-0794-7
P577
2011-08-16T00:00:00Z